Schering-Plough Corporation: Q2 1999 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, for Schering-Plough Corporation, a worldwide research-based pharmaceutical company. Effective January 1, 1999, the company reorganized its internal structure to report as a single segment, consolidating its previous pharmaceuticals and healthcare units. The company focuses on the discovery, development, and marketing of prescription pharmaceuticals, with secondary applications in animal health and over-the-counter (OTC) markets.
Key Financial Metrics
| Metric | Q2 1999 | Q2 1998 | YTD 1999 | YTD 1998 |
|---|---|---|---|---|
| Net Sales | $2,451 million | $2,124 million | $4,637 million | $4,032 million |
| Net Income | $547 million | $455 million | $1,086 million | $905 million |
| Diluted EPS | $0.37 | $0.31 | $0.73 | $0.61 |
| Operating Cash Flow (YTD) | $767 million (vs. $841 million YTD 1998) | |||
| Cash & Equivalents | $1,523 million (as of June 30, 1999) | |||
| Debt (Short-term + Current LT) | $749 million (as of June 30, 1999) | |||
| Effective Tax Rate | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 15% in Q2 and 15% YTD compared to 1998. Excluding foreign currency effects, Q2 sales grew 16%.
- Profitability: Net income rose 20% in both the quarter and YTD periods. Income before taxes represented 29.6% of sales in Q2 (up from 28.4% in 1998).
- Product Performance:
- Allergy & Respiratory: Sales grew 17% in Q2, driven by the CLARITIN brand ($819 million in Q2 sales).
- Anti-infectives & Anticancer: Sales surged 50% in Q2, primarily due to the 1998 U.S. launch of REBETRON Combination Therapy.
- Cardiovasculars: Sales declined 17% in Q2 due to generic competition affecting IMDUR and NORMODYNE.
- Expenses: R&D spending increased 14% in Q2 to $297 million (12.1% of sales). Selling, general, and administrative expenses rose slightly as a percentage of sales due to increased product promotion.
- Cash Flow: Operating cash flow decreased $74 million YTD to $767 million, primarily due to higher accounts receivable from sales growth and reduced accounts payable.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D spending for the full year 1999 to increase by more than 15% over the prior year. The company maintains sufficient liquidity to meet operating needs.
- Capital Allocation: The company repurchased $425 million of common shares YTD (57% of the $1 billion program complete) and increased the quarterly dividend by 14% to $0.125 per share.
- Year 2000 (Y2K) Readiness: The company estimates a maximum project cost of $95 million, with $53 million incurred as of June 30, 1999. Remediation of critical IT and non-IT systems is 99% complete. Management believes Y2K will not materially affect internal operations but warns of potential disruption from third-party vendors.
- Legal and Patent Risks:
- Antitrust: The company is defending against over 160 antitrust actions regarding price-fixing allegations. While a federal class action was settled for $22 million, state cases remain pending, though recent rulings in Alabama may lead to dismissals.
- Patent Litigation: Multiple generic manufacturers (Geneva, Copley, Teva, Novex, Zenith) have filed ANDAs for generic CLARITIN, challenging patent validity. Schering-Plough has filed suits alleging willful infringement but notes no assurance of prevailing.
- Market Risks: Exposure to foreign currency and interest rate changes is not considered material. However, the company faces competitive pricing pressure from managed care and government cost-containment programs globally.
Investor Verification Checklist
- Verify the status of pending antitrust litigation, specifically the Alabama state court cases and the FTC investigation.
- Monitor the outcome of CLARITIN patent infringement lawsuits filed against generic manufacturers (Geneva, Copley, Teva, Novex, Zenith).
- Assess the impact of generic competition on cardiovascular product lines (IMDUR, NORMODYNE) in future quarters.
- Review the progress of the Year 2000 remediation project and communications with third-party vendors regarding their readiness.
- Confirm the sustainability of the 15%+ R&D spending increase and its impact on future product pipelines.